Immucell (ICCC) Operating Leases (2020 - 2026)

Immucell (ICCC) has reported Operating Leases for 7 consecutive years, with $4.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Leases fell 2.92% year-over-year to $4.0 million; the trailing twelve-month figure through Jun 2026 stood at $4.0 million (down 2.92% YoY), and the FY2025 full-year result was $4.0 million, down 2.89% from the prior year.
• Operating Leases was little changed at $4.0 million in Q2 2026 per ICCC's latest filing, from $4.0 million in the prior quarter.
• Across five years, Operating Leases topped out at $4.7 million in Q1 2024 and bottomed at $1.1 million in Q2 2022.
• Historically, Operating Leases has averaged $3.5 million across 5 years, with a median of $4.1 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Operating Leases soared 299.21% in 2023, then retreated 11.8% in 2025.
• Over 5 years, Operating Leases stood at $2.2 million in 2022, then surged by 81.27% to $4.1 million in 2023, then increased by 1.28% to $4.1 million in 2024, then fell by 2.89% to $4.0 million in 2025, then rose by 0.32% to $4.0 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $4.0 million, $4.0 million, and $4.1 million for Q2 2026, Q4 2025, and Q3 2025 respectively.